NCT00296699View on ClinicalTrials.gov

A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2007

Conditions
Atypical Depression
Interventions
DRUG

Duloxetine

"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~\* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."

Trial Locations (1)

10032

Depression Evaluation Service - New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

New York State Psychiatric Institute

OTHER

NCT00296699 - A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression | Biotech Hunter | Biotech Hunter